overcoming ovarian cancer chemoresistance

Download Overcoming Ovarian Cancer Chemoresistance ebooks in PDF, epub, tuebl, textbook from Skinvaders.Com. Read online Overcoming Ovarian Cancer Chemoresistance books on any device easily. We cannot guarantee that Overcoming Ovarian Cancer Chemoresistance book is available. Click download or Read Online button to get book, you can choose FREE Trial service. READ as many books as you like (Personal use).

Overcoming Ovarian Cancer Chemoresistance
Author : Goli Samimi,Christina Annunziata
Publisher : Academic Press
Release Date : 2020-11-19
ISBN 10 : 0128198419
Pages : 188 pages
GET BOOK!

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
Author : Andrew Freywald,Franco Vizeacoumar
Publisher : Academic Press
Release Date : 2020-12-04
ISBN 10 : 0128213116
Pages : 308 pages
GET BOOK!

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies

Cancer Drug Resistance Research Perspectives
Author : Liman S. Torres
Publisher : Nova Publishers
Release Date : 2007
ISBN 10 : 9781600215728
Pages : 223 pages
GET BOOK!

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common. The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs. This book presents new and important research in this field.

Therapeutic Strategies to Overcome ALK Resistance in Cancer
Author : Luc Friboulet
Publisher : Academic Press
Release Date : 2021-01-18
ISBN 10 : 0128217790
Pages : 216 pages
GET BOOK!

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment. Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC

Progress in Cancer Drug Resistance Research
Author : Robert A. Parsons
Publisher : Nova Publishers
Release Date : 2007
ISBN 10 : 9781600218224
Pages : 223 pages
GET BOOK!

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100 percent effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common.The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anti-cancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information on how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.

Cancer Cell Chemoresistance and Chemosensitization
Author : Ajaikumar B. Kunnumakkara,Devivasha Bordoloi,Javadi Monisha
Publisher : World Scientific
Release Date : 2018
ISBN 10 : 9813208570
Pages : 329 pages
GET BOOK!

Ovarian Cancer
Author : George Coukos,Andrew Berchuck,Robert Ozols
Publisher : Springer Science & Business Media
Release Date : 2008-06-06
ISBN 10 : 0387689699
Pages : 308 pages
GET BOOK!

Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for Conferences in all fields of Science, Engineering, Arts, and Humanities. The purpose of the Conferences is to bring together individuals with common interests to examine the emerging and most advanced aspects of their particular field. The Symposium on Ovarian Cancer: State of the Art and Future Directions intends to bring together international experts interested in the development of novel diagnostic, prognostic and therapeutic tools for ovarian cancer. The meeting will function as a think tank where clinicians, translational and basic scientists, and parties from the biotechnology and pharmaceutical industry will get together to review recent advances in clinical research and translational science in ovarian cancer and define areas of future research opportunities and priorities.

Drug Resistance in Oncology
Author : S. Bernal
Publisher : CRC Press
Release Date : 1997-08-21
ISBN 10 : 9781420002096
Pages : 416 pages
GET BOOK!

This timely new reference integrates the latest clinical results and laboratory studies on the resistance of specific cancers to chemotherapeutic drugs-covering drug resistance in lung, breast, ovary, and colon cancer as well as hematological malignancies.

Drug Resistance in Cancer Therapy
Author : Robert F. Ozols
Publisher : Springer Science & Business Media
Release Date : 2012-12-06
ISBN 10 : 1461316014
Pages : 210 pages
GET BOOK!

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good in-depth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfor tunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes that aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion: first, by dividing the oncology literature into specific subdivisions such as lung can cer, genitourinary cancer, and pediatric oncology; second, by asking emi nent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more.

Ovarian Cancers
Author : National Academies of Sciences, Engineering, and Medicine,Institute of Medicine,Board on Health Care Services,Committee on the State of the Science in Ovarian Cancer Research
Publisher : National Academies Press
Release Date : 2016-05-25
ISBN 10 : 0309380464
Pages : 396 pages
GET BOOK!

In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.

Ovarian Cancer
Author : Omer Devaja,Andreas Papadopoulos
Publisher : BoD – Books on Demand
Release Date : 2018-10-24
ISBN 10 : 1789843332
Pages : 364 pages
GET BOOK!

Ovarian cancer management is a rapidly changing field with new treatment agents available as a result of a greater understanding of the pathogenesis of this disease. In addition, both surgical and chemotherapeutic treatment strategies are evolving to maximise response in this disease. This book brings together leading specialists from around the world to discuss and outline a variety of new concepts in ovarian cancer, ranging from molecular biology and genetics through screening to both surgical and chemotherapeutic management.

Resistance to Photodynamic Therapy in Cancer
Author : Valentina Rapozzi,Giulio Jori
Publisher : Springer
Release Date : 2014-12-11
ISBN 10 : 3319127306
Pages : 248 pages
GET BOOK!

This volume provides a comprehensive review of resistance induced by photodynamic therapy (PDT) in tumor cells. Understanding the underlying mechanisms in this process leads to the improvement of therapeutic modality, in combination with chemotherapy, immunotherapy, and radiotherapy. Photodynamic therapy is a minimally invasive therapeutic procedure that can exert a selective or preferential cytotoxic activity toward malignant cells. The procedure involves administration of an intrinsically non-toxic photosensitizing agent (PS) followed by irradiation at a wavelength corresponding to a visible absorption band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Studies reveal that PDT can be curative, particularly in early stage tumors and this volume explores the potential of PDT, but also reveals strategic approaches to overcome resistance in tumor cells.

Encyclopedia of Cancer
Author : Manfred Schwab
Publisher : Springer Science & Business Media
Release Date : 2008-09-23
ISBN 10 : 3540368477
Pages : 3235 pages
GET BOOK!

This comprehensive encyclopedic reference provides rapid access to focused information on topics of cancer research for clinicians, research scientists and advanced students. Given the overwhelming success of the first edition, which appeared in 2001, and fast development in the different fields of cancer research, it has been decided to publish a second fully revised and expanded edition. With an A-Z format of over 7,000 entries, more than 1,000 contributing authors provide a complete reference to cancer. The merging of different basic and clinical scientific disciplines towards the common goal of fighting cancer makes such a comprehensive reference source all the more timely.

Gynecologic Oncology
Author : Robert F. Ozols
Publisher : Taylor & Francis
Release Date : 1998
ISBN 10 : 9780792380702
Pages : 387 pages
GET BOOK!

Text focusing primarily on ovarian cancer. Explores advances in cytoreductive surgery, problems in screening, new drugs, chemotherapy, hereditary basis for gynecologic malignancies, molecular genetics, molecular biology, and new biologic therapies. For researchers and pathologists, surgeons, chemotherapists, and practitioners.

Overcoming Drug Resistance in Gynecologic Cancers
Author : N.A
Publisher : Academic Press
Release Date : 2021-05-15
ISBN 10 : 9780128242995
Pages : 300 pages
GET BOOK!

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Ovarian Cancer: New Insights for the Healthcare Professional: 2011 Edition
Author : N.A
Publisher : ScholarlyEditions
Release Date : 2012-01-09
ISBN 10 : 1464900604
Pages : 274 pages
GET BOOK!

Ovarian Cancer: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Ovarian Cancer. The editors have built Ovarian Cancer: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Ovarian Cancer in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Ovarian Cancer: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Ovarian Cancer
Author : Robert F. Ozols,American Cancer Society
Publisher : PMPH-USA
Release Date : 2003
ISBN 10 : 9781550090963
Pages : 246 pages
GET BOOK!

"Featuring more than 300 illustrations, the text covers pathology, biology, epidemiology, genetics, and screening through surgical management, the latest in chemotherapeutic regimens, and finally, palliative care"--P. [4] of cover.

Cancer Drug Resistance
Author : Thomas C. Hall
Publisher : N.A
Release Date : 1986
ISBN 10 :
Pages : 235 pages
GET BOOK!

Intraperitoneal Therapy for Ovarian Cancer
Author : David Alberts,Mary C. Clouser,Lisa M. Hess
Publisher : Springer Science & Business Media
Release Date : 2010-08-24
ISBN 10 : 9783642121302
Pages : 153 pages
GET BOOK!

Intraperitoneal chemotherapy is increasingly being used as first-line treatment for ovarian cancer. Nevertheless, it is difficult for the oncologist to find a definitive text that documents both the fundamental methods required to optimize therapy and the up-to-date results of phase I, II, and III clinical trials. With this in mind, the editors of Intraperitoneal Chemotherapy have assembled a team of highly experienced clinicians and researchers to cover every aspect of the subject. The topics addressed include treatment principles, patient, drug, and catheter selection, administration guidelines, the role of hyperthermia, supportive care requirements, novel drugs, and the most recent results of clinical trials. This book will be an invaluable source of information for both practicing clinical oncologists and oncologists in training.

Chemosensitivity Testing in Oncology
Author : Uwe Reinhold,Wolfgang Tilgen
Publisher : Springer Science & Business Media
Release Date : 2002-10-31
ISBN 10 : 9783540434689
Pages : 245 pages
GET BOOK!

Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells.